查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587475

美国临床试验市场规模、份额、趋势分析报告：按阶段、按适应症、按研究设计、按申办者、按服务、细分市场预测，2025-2030 年

U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication by Study Design, By Sponsor, By Service, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国临床试验市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年美国临床试验市场规模将达到577.9亿美元，2025年至2030年复合年增长率为6.30%。

美国慢性病盛行率的上升和对临床试验的需求不断增长正在推动市场成长。

预计未来八年被诊断出罹患癌症的人数将增加数倍。儘管肿瘤学领域的研究显着增加了倖存者的数量，但预计全球癌症患者的数量将会增加。胰臟癌预后较差，存活期仅1～3年。每天约有 13 人被诊断出患有胃肠道基质肿瘤。美国每年诊断出超过 60,000 例肾细胞癌新病例，这表明癌症盛行率不断增加，并且需要针对多种癌症进行有效治疗方法。由于美国疫情爆发，研发投资预计将增加，推动产业成长。

COVID-19 大流行已停止了新的研究计划，并将资源重新分配给其他疾病。由于边境关闭，临床试验样本的供应链也受到干扰。因此，这个市场一片混乱。然而，COVID-19 因应措施开拓了新市场，彻底改变了临床试验的进行方式。分散/虚拟临床试验就是这样的方法之一。虚拟临床试验在目前的 COVID-19 情况下发挥着非常重要的作用。虚拟就诊和远端患者监护为参与者提供了选择和安心，以最大限度地降低风险。监控小工具、软体工具和行动电话让参与者家用中完成实验。

美国临床试验市场报告亮点

  • 2024年，三期试验占据了最高的销售份额。这些临床试验更为重要，因为它们涉及 300 至 3000 名参与者，而且持续时间较长。因此，这是最昂贵的阶段。
  • 从试验设计来看，干预设计细分市场在美国市场占据主导地位，在 2024 年占据最大的销售份额。
  • 有迹象表明，肿瘤学领域在 2024 年占据了最大的收益占有率。这种增长是由于癌症患者数量的增加。因此，大量资金花在肿瘤学临床试验。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国临床试验市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 配套市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 监管状况
  • 技术景观
  • 定价模式分析
  • 临床试验定量分析，2024
  • 美国临床试验市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析
  • 产品平臺分阶段分析
    • 正在开发的治疗方法
    • 正在开发的疫苗

第四章美国临床试验市场：阶段估计与趋势分析

  • 细分仪表板
  • 临床试验市场：2024 年和 2030 年阶段变异分析和市场占有率
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章美国临床试验市场：试验设计估算与趋势分析

  • 细分仪表板
  • 临床试验市场：研究设计变异分析和市场占有率，2024 年和 2030 年
  • 侵扰性的
  • 观察性的
  • 扩展访问

第六章美国临床试验市场：适应症估计与趋势分析

  • 细分仪表板
  • 临床试验市场：适应症变异分析和市场占有率，2024 年和 2030 年
  • 自体免疫/发炎
    • 类风湿性关节炎
    • 多发性硬化症
    • 骨关节炎
    • 大肠激躁症（IBS）
    • 其他的
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 肿瘤学
    • 血癌
    • 固态肿瘤
    • 其他的
  • 中枢神经系统症状
    • 癫痫
    • 帕金森氏症 (PD)
    • 亨丁顿舞蹈症
    • 中风
    • 创伤性脑损伤 (TBI)
    • 肌萎缩侧索硬化症（ALS）
    • 肌肉再生
    • 其他的
  • 糖尿病
  • 肥胖
  • 心血管
  • 其他的

第七章美国临床试验市场：依试验设计与适应症进行估算与趋势分析

  • 细分仪表板
  • 临床试验市场：适应症变异分析和市场占有率，2024 年和 2030 年
  • 自体免疫/发炎
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 疼痛管理
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 肿瘤学
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 中枢神经系统症状
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 糖尿病
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 肥胖
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 心血管
    • 侵扰性的
    • 观察性的
    • 扩展访问
  • 其他的
    • 侵扰性的
    • 观察性的
    • 扩展访问

第八章美国临床试验市场：服务评估与趋势分析

  • 细分仪表板
  • 临床试验市场：申办者变化分析和市场占有率，2024 年和 2030 年
  • 通讯协定设计
  • 场地标识
  • 病患招募
  • 化验服务
  • 生物分析测试服务
  • 临床试验资料管理服务
  • 其他的

第九章美国临床试验市场：申办者预估及趋势分析

  • 细分仪表板
  • 临床试验市场：申办者变化分析和市场占有率，2024 年和 2030 年
  • 製药和生物製药公司
  • 医疗设备公司

第10章竞争格局

  • 市场参与企业分类
    • 市场领导者
    • 新兴玩家
  • 2024 年市场分析
  • 主要企业简介
    • IQVIA
    • Fortrea Inc.
    • PAREXEL International Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories
    • ICON Plc
    • Wuxi AppTec Inc.
    • Medpace
    • Syneos Health
    • AstraZeneca
    • Merck &Co.
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Pfizer
    • Caidya
Product Code: GVR-4-68039-580-4

U.S. Clinical Trials Market Growth & Trends:

The U.S. clinical trials market size is estimated to reach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

U.S. Clinical Trials Market Report Highlights:

  • In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
  • By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
  • Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Regulatory Landscape
  • 3.4. Technological Landscape
  • 3.5. Pricing Model Analysis
  • 3.6. Clinical Trial Volume Analysis, 2024
  • 3.7. U.S. Clinical Trials Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
    • 3.7.3. COVID-19 Impact Analysis
  • 3.8. Product Pipeline Analysis by Stage
    • 3.8.1. Therapeutics in Development
    • 3.8.2. Vaccines in Development

Chapter 4. U.S. Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Phase I
    • 4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Phase II
    • 4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Phase III
    • 4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Phase IV
    • 4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Interventional
    • 5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Observational
    • 5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Expanded Access
    • 5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Autoimmune/Inflammation
    • 6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Rheumatoid Arthritis
      • 6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Multiple Sclerosis
      • 6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. Osteoarthritis
      • 6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Irritable Bowel Syndrome (IBS)
      • 6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Others
      • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Pain Management
    • 6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Chronic Pain
      • 6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Acute Pain
      • 6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Oncology
    • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Blood Cancer
      • 6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Solid Tumors
      • 6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Others
      • 6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. CNS Conditions
    • 6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Epilepsy
      • 6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Parkinson's Disease (PD)
      • 6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Huntington's Disease
      • 6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Stroke
      • 6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Traumatic Brain Injury (TBI)
      • 6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8. Muscle Regeneration
      • 6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.9. Others
      • 6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Diabetes
    • 6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Obesity
    • 6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Cardiovascular
    • 6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Autoimmune/Inflammation
    • 7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Interventional
      • 7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Observational
      • 7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Expanded Access
      • 7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Pain Management
    • 7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Interventional
      • 7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Observational
      • 7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Expanded Access
      • 7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Interventional
      • 7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Observational
      • 7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. Expanded Access
      • 7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. CNS Conditions
    • 7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Interventional
      • 7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Observational
      • 7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Expanded Access
      • 7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Diabetes
    • 7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Interventional
      • 7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Observational
      • 7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. Expanded Access
      • 7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Obesity
    • 7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. Interventional
      • 7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Observational
      • 7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. Expanded Access
      • 7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Cardiovascular
    • 7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.2. Interventional
      • 7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.3. Observational
      • 7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.4. Expanded Access
      • 7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.2. Interventional
      • 7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.3. Observational
      • 7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.4. Expanded Access
      • 7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
  • 8.3. Protocol Designing
    • 8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Site Identification
    • 8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Patient Recruitment
    • 8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Laboratory Services
    • 8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Bioanalytical Testing Services
    • 8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Clinical Trial Data Management Services
    • 8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9. Others
    • 8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. U.S. Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
  • 9.3. Pharmaceutical & Biopharmaceutical Companies
    • 9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Medical Device Companies
    • 9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Position Analysis, 2024
  • 10.3. Key Company Profiles
    • 10.3.1. IQVIA
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Fortrea Inc.
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. PAREXEL International Corporation
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Thermo Fisher Scientific Inc.
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Charles River Laboratories
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. ICON Plc
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Wuxi AppTec Inc.
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Medpace
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Syneos Health
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. AstraZeneca
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Merck & Co.
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Eli Lilly and Company
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Novo Nordisk A/S
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Pfizer
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Caidya
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. U.S. Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 4. U.S. Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5. U.S. Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 6. U.S. Clinical Trials Market, Indication by Study Design, 2018 - 2030 (USD Million)
  • Table 7. U.S. Clinical Trials Market, by Service, 2018 - 2030 (USD Million)
  • Table 8. U.S. Clinical Trials Market, by Sponsor, 2018 - 2030 (USD Million)
  • Table 9. Participant's Overview
  • Table 10. Financial Performance
  • Table 11. Service Benchmarking
  • Table 12. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Clinical Trials Market, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 PESTEL by SWOT Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 U.S. Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Clinical Trials Market, for Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Clinical Trials Market, for Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Clinical Trials Market, for Observational, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Clinical Trials Market, for Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Clinical Trials Market, for Autoimmune/Inflammation, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Clinical Trials Market, for Rheumatoid Arthritis, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Clinical Trials Market, for Multiple Sclerosis, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Clinical Trials Market, for Osteoarthritis, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Clinical Trials Market, for Irritable Bowel Syndrome (IBS), 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Clinical Trials Market, for Pain Management, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Clinical Trials Market, for Chronic Pain, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Clinical Trials Market, for Acute Pain, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Clinical Trials Market, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Clinical Trials Market, for Blood Cancer, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Clinical Trials Market, for Solid Tumors, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Clinical Trials Market, for CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Clinical Trials Market, for Epilepsy, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Clinical Trials Market, for Parkinson's Disease (PD), 2018 - 2030 (USD Million)
  • Fig. 35 U.S. Clinical Trials Market, for Huntington's Disease, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Clinical Trials Market, for Stroke, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Clinical Trials Market, for Traumatic Brain Injury (TBI), 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Clinical Trials Market, for Amyotrophic Lateral Sclerosis (ALS), 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Clinical Trials Market, for Muscle Regeneration, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Clinical Trials Market, for Diabetes, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Clinical Trials Market, for Obesity, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Clinical Trials Market, for Cardiovascular, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Clinical Trials Market, for Autoimmune/Inflammation Interventional, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. Clinical Trials Market, for Autoimmune/Inflammation Observational, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. Clinical Trials Market, for Autoimmune/Inflammation Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Clinical Trials Market, for Pain Management Interventional, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. Clinical Trials Market, for Pain Management Observational, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. Clinical Trials Market, for Pain Management Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. Clinical Trials Market, for Oncology Interventional, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Clinical Trials Market, for Oncology Observational, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. Clinical Trials Market, for Oncology Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. Clinical Trials Market, for CNS Conditions Interventional, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. Clinical Trials Market, for CNS Conditions Observational, 2018 - 2030 (USD Million)
  • Fig. 56 U.S. Clinical Trials Market, for CNS Conditions Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. Clinical Trials Market, for Diabetes Interventional, 2018 - 2030 (USD Million)
  • Fig. 58 U.S. Clinical Trials Market, for Diabetes Observational, 2018 - 2030 (USD Million)
  • Fig. 59 U.S. Clinical Trials Market, for Diabetes Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 60 U.S. Clinical Trials Market, for Obesity Interventional, 2018 - 2030 (USD Million)
  • Fig. 61 U.S. Clinical Trials Market, for Obesity Observational, 2018 - 2030 (USD Million)
  • Fig. 62 U.S. Clinical Trials Market, for Obesity Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 63 U.S. Clinical Trials Market, for Cardiovascular Interventional, 2018 - 2030 (USD Million)
  • Fig. 64 U.S. Clinical Trials Market, for Cardiovascular Observational, 2018 - 2030 (USD Million)
  • Fig. 65 U.S. Clinical Trials Market, for Cardiovascular Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. Clinical Trials Market, for Other Indications Interventional, 2018 - 2030 (USD Million)
  • Fig. 67 U.S. Clinical Trials Market, for Other Indications Observational, 2018 - 2030 (USD Million)
  • Fig. 68 U.S. Clinical Trials Market, for Other Indications Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 69 U.S. Clinical Trials Market, for Protocol Designing, 2018 - 2030 (USD Million)
  • Fig. 70 U.S. Clinical Trials Market, for Site Identification, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. Clinical Trials Market, for Patient Recruitment, 2018 - 2030 (USD Million)
  • Fig. 72 U.S. Clinical Trials Market, for Laboratory Services, 2018 - 2030 (USD Million)
  • Fig. 73 U.S. Clinical Trials Market, for Bioanalytical Testing Services, 2018 - 2030 (USD Million)
  • Fig. 74 U.S. Clinical Trials Market, for Clinical Trial Data Management Services, 2018 - 2030 (USD Million)
  • Fig. 75 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 76 U.S. Clinical Trials Market, for Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. Clinical Trials Market, for Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 78 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)